all report title image
  • Published On : Feb 2020
  • Code : CMI241
  • Industry : Pharmaceutical
  • Pages : 175
  • Formats :

Non-small Cell Lung Cancer Treatment Market – Insights

There is  no exact reason defined yet by doctors behind the causes of lung cancer but few causes include smoking, air pollution, exposure to mineral and metal dust, and radiation treatment of chest or breast. Lung cancer symptoms are not noticeable in its early stage as these symptoms are considered for other type of illness such as pneumonia or collapsed lung. Some symptoms of lung cancer include chest pain, harsh/raspy sound while breathing, wheezing, weight loss, continuous cough, hoarseness or voice changes, shortness of breath, lung problems such as bronchitis or pneumonia and others. Moreover, if it spreads  through the bloodstream or the lymphatics into other parts of the body then it exhibits symptoms such as bone pain, weakness in arm or leg, yellow skin, yellow eyes, headache, and seizures.

Some diagnosis test are performed by doctors to detect lung cancer, which include diagnostic imaging test such as X-ray, MRI, Ultrasound, CT scan, and PET scan, and also by diagnosing mucous, which the patient can cough up to check the presence of cancer cells, which is called as sputum cytology. By taking the cells of lungs from abnormal growth area of your lung or from the fluid of lungs through the procedure called as fine needle aspiration biopsy, bronchoscopy, and mediastinoscopy, lung cancer can be diagnosed.

The global non-small cell lung cancer treatment market was estimated to be valued at US$ 19,161.7 million in 2019, and is expected to exhibit a CAGR of 9.3% over the forecast period (2019-2027).

Global Non-small Cell Lung Cancer Treatment Market Share (%) Analysis, By Type, 2019

Non Small Cell Lung Cancer  | Coherent Market Insights

Source: Coherent Market Insights Analysis (2020)

Increasing new drug approvals for the treatment of Non-small cell lung cancer is expected to drive the market growth

The increasing number of new drug approvals by regulatory authority for the treatment of Non-small cell lung cancer is expected to drive growth of the market. Key players operating in the market are focused on investing in R&D activities to cater to rising demand for Non-small cell lung cancer treatment.

In May 2019, EMA’s Committee for Medicinal Products for Human Use (CHMP) provided a positive opinion for Pfizer Inc.’s LORVIQUA drug that is indicated for ALK-positive advanced Non-small cell lung cancer adult patients, who were previously-treated with alectinib or ceritinib as the first anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) therapy.

For instance, in August 2019, Roche Holding received the U.S. Food and Drug Administration (FDA) approval for Rozlytrek (entrectinib), which is indicated for the treatment of adults with ROS1-positive, metastatic Non-small cell lung cancer.

Moreover, in May, 2019, Pfizer Inc. received the European Commission’s (EC) marketing authorization for the LORVIQUA drug, a monotherapy drug used for the treatment of anaplastic lymphoma kinase (ALK)-positive advanced Non-small cell lung cancer (NSCLC).

Global Non-small Cell Lung Cancer Treatment Market – Restraints

However, high cost of drugs is a major barrier for patients to adopt these drugs easily. High cost of drugs used in Non-small cell lung cancer treatment is a major factor that is expected to restrain growth of the market. For instance, in 2017, according to Lung Cancer, Oncology Journal, the total cost associated with lung cancer care in the U.S. was around US$ 13.9 billion, with around 43% (US$ 6 billion) of the costs occurring during initial care and 41% (US$ 5.8 billion) occurring within the last year of life. The prices of drugs increased over the time and it was observed in drugs that are covered under outpatient prescription drug benefit. The price of these drugs ranged from US$ 2,293/month in 2010 to US$ 14,079/month in 2017.

Global Non-small Cell Lung Cancer Treatment Market - Regional Insights

On the basis of region, the global Non-small cell lung cancer treatment market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to hold a dominant position in the global aptamers market, owing to increasing number of drug approvals by the U.S. Food and Drug Administration for the treatment of Non-small cell lung cancer. For instance, in April 2018, AstraZeneca Pharmaceuticals LP received the U.S. Food and Drug Administration approval for its Tagrisso (osimertinib), first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC), whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations. The drug was approved by Health Canada in July 2018.

Asia Pacific is the expected to be fastest growing region in the global Non-small cell lung cancer treatment market, owing to increasing prevalence of lung cancer. For instance, according to the Center for Cancer Control and Information Services 2018 report, around 125,100 cases of lung cancer were reported in Japan in 2018.

Global Non-small Cell Lung Cancer Treatment Market Value (US$ Mn) & Y-o-Y Growth (%), 2016-2027

Non Small Cell Lung Cancer  | Coherent Market Insights

Source: Coherent Market Insights Analysis (2020)

Global Non-small Cell Lung Cancer Treatment Market - Competitive Landscape

Key players operating in the global Non-small cell lung cancer treatment market include Pfizer Inc., AstraZeneca plc, F. Hoffmann-La Roche Ltd., Eli Lilly and Company, Boehringer Ingelheim GMBH, Novartis AG, Bristol-Myers Squibb Company, and Merck & Co., Inc.

 

Cancer is a disease, in which cell grows abnormally and may cause a tumor. In lung cancer, the cells of lungs starts to grow in uncontrolled manner later form a tumor and that can be spread into other body parts. Small cell lung cancer and Non-small cell lung cancer are two main types of lung cancer. According to the stats of Lung Cancer Alliance (leading non-profit organization dedicated to fighting lung cancer), out of overall lung cancer, around 80 to 85% cases found are of Non-small cell lung cancer type and 15-20% cases found are of small cell lung cancer type. Different and commonly diagnosed types of Non-small cell lung cancer (NSCLC) include adenocarcinoma, squamous cell carcinoma, large cell carcinoma, and large cell neuroendocrine tumors. Out of all these types adenocarcinoma and squamous cell carcinoma accounts around 60% of lung cancer.

Market Dynamics

Increasing prevalence of lung cancer is a major factor that is expected to drive growth of the Non-small cell lung cancer treatment market. Non-small cell lung cancer is the leading cause of cancer-related mortality in the U.S. For instance, according to data published by the American Cancer Society, Inc. (ACSI), NSCLC is the second most common type of cancer found in both men and women. Moreover, as per the estimation of ACSI, in 2017, it was estimated that around 222,500 new cases of lung cancer, and 155,870 deaths were reported due to lung cancer in the U.S.

Moreover, the National Cancer Institute estimated that in 2018, around 2 million new cases (or 11% of total cancer cases) of lung cancer were diagnosed in the U.S.

Key features of the study:

  • This report provides in-depth analysis of the global Non-small cell lung cancer treatment market, market size (US$ Mn), and compound annual growth rate (CAGR (%) for the forecast period, 2019-2027, considering 2018 as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by leading players
  • It profiles key players in the global Non-small cell lung cancer treatment market based on the following parameters: company overview, financial performance, product portfolio, geographical presence, key developments, and strategies
  • Key players covered as a part of this study include Pfizer Inc., AstraZeneca plc, F. Hoffmann-La Roche Ltd., Eli Lilly and Company, Boehringer Ingelheim GMBH, Novartis AG, Bristol-Myers Squibb Company, and Merck & Co., Inc.
  • Insights from this report would allow marketers and management authorities of companies to make informed decisions with respect to future product launches, governmental initiatives, technological upgradation, market expansion, and marketing tactics
  • The global Non-small cell lung cancer treatment market report caters to various stakeholders in this industry, which include investors, product manufacturers, distributors, and suppliers for global Non-small cell lung cancer treatment market, research and consulting firms, new entrants, and financial analysts

Detailed Segmentation:

  • Global Non-small Cell Lung Cancer Treatment Market, by Type:
    • Adenocarcinoma
    • Squamous Cell Carcinoma
    • Large Cell Carcinoma
    • Large Cell Neuroendocrine Tumors
  • Global Non-small Cell Lung Cancer Treatment Market, by Treatment:
    • Chemotherapy
    • Targeted Therapy
      • Bevacizumab (Avastin)
      • Necitumumab (Portrazza)
      • Ramucirumab (Cyramza)
    • Immunotherapy
      • Nivolumab (Opdivo)
      • Atezolizumab (Tecentriq)
      • Others
  • Global Non-small Cell Lung Cancer Treatment Market, by Region:
    • North America
      • By Country:
        • U.S.
        • Canada
      • By Type:
        • Adenocarcinoma
        • Squamous Cell Carcinoma
        • Large Cell Carcinoma
        • Large Cell Neuroendocrine Tumors
      • By Treatment:
        • Chemotherapy
        • Targeted Therapy
          • Bevacizumab (Avastin)
          • Necitumumab (Portrazza)
          • Ramucirumab (Cyramza)
        • Immunotherapy
          • Nivolumab (Opdivo)
          • Atezolizumab (Tecentriq)
          • Others
    • Europe
      • By Country:
        • U.K.
        • Germany
        • Italy
        • Spain
        • France
        • Russia
        • Rest of Europe
      • By Type:
        • Adenocarcinoma
        • Squamous Cell Carcinoma
        • Large Cell Carcinoma
        • Large Cell Neuroendocrine Tumors
      • By Treatment:
        • Chemotherapy
        • Targeted Therapy
          • Bevacizumab (Avastin)
          • Necitumumab (Portrazza)
          • Ramucirumab (Cyramza)
        • Immunotherapy
          • Nivolumab (Opdivo)
          • Atezolizumab (Tecentriq)
          • Others
    • Asia Pacific
      • By Country:
        • Australia
        • India
        • China
        • Japan
        • ASEAN
        • South Korea
        • Rest of Asia Pacific
      • By Type:
        • Adenocarcinoma
        • Squamous Cell Carcinoma
        • Large Cell Carcinoma
        • Large Cell Neuroendocrine Tumors
      • By Treatment:
        • Chemotherapy
        • Targeted Therapy
          • Bevacizumab (Avastin)
          • Necitumumab (Portrazza)
          • Ramucirumab (Cyramza)
        • Immunotherapy
          • Nivolumab (Opdivo)
          • Atezolizumab (Tecentriq)
          • Others
    • Latin America
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
      • By Type:
        • Adenocarcinoma
        • Squamous Cell Carcinoma
        • Large Cell Carcinoma
        • Large Cell Neuroendocrine Tumors
      • By Treatment:
        • Chemotherapy
        • Targeted Therapy
          • Bevacizumab (Avastin)
          • Necitumumab (Portrazza)
          • Ramucirumab (Cyramza)
        • Immunotherapy
          • Nivolumab (Opdivo)
          • Atezolizumab (Tecentriq)
          • Others
    • Middle East
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
      • By Type:
        • Adenocarcinoma
        • Squamous Cell Carcinoma
        • Large Cell Carcinoma
        • Large Cell Neuroendocrine Tumors
      • By Treatment:
        • Chemotherapy
        • Targeted Therapy
          • Bevacizumab (Avastin)
          • Necitumumab (Portrazza)
          • Ramucirumab (Cyramza)
        • Immunotherapy
          • Nivolumab (Opdivo)
          • Atezolizumab (Tecentriq)
          • Others
    • Africa
      • By Country/Region:
        • South Africa
        • Central Africa
        • North Africa
      • By Type:
        • Adenocarcinoma
        • Squamous Cell Carcinoma
        • Large Cell Carcinoma
        • Large Cell Neuroendocrine Tumors
      • By Treatment:
        • Chemotherapy
        • Targeted Therapy
          • Bevacizumab (Avastin)
          • Necitumumab (Portrazza)
          • Ramucirumab (Cyramza)
        • Immunotherapy
          • Nivolumab (Opdivo)
          • Atezolizumab (Tecentriq)
          • Others
  • Company Profiles
    • Pfizer Inc.*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies
    • AstraZeneca plc
    • F. Hoffmann-La Roche Ltd.
    • Eli Lilly and Company
    • Boehringer Ingelheim GMBH
    • Novartis AG
    • Bristol-Myers Squibb Company
    • Merck & Co., Inc.

 “*” marked represents similar segmentation in other categories in the respective section.

Related Reports

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo